
## Steven A Julious

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7141846/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics, 2005, 4, 287-291.	1.3	1,632
2	Reducing waste from incomplete or unusable reports of biomedical research. Lancet, The, 2014, 383, 267-276.	13.7	982
3	Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Statistical Methods in Medical Research, 2016, 25, 1057-1073.	1.5	903
4	An audit of sample sizes for pilot and feasibility trials being undertaken in the United Kingdom registered in the United Kingdom Clinical Research Network database. BMC Medical Research Methodology, 2013, 13, 104.	3.1	523
5	Sample sizes for clinical trials with Normal data. Statistics in Medicine, 2004, 23, 1921-1986.	1.6	451
6	Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open, 2017, 7, e015276.	1.9	335
7	A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. Trials, 2013, 14, 166.	1.6	295
8	The statistical interpretation of pilot trials: should significance thresholds be reconsidered?. BMC Medical Research Methodology, 2014, 14, 41.	3.1	266
9	Using confidence intervals around individual means to assess statistical significance between two means. Pharmaceutical Statistics, 2004, 3, 217-222.	1.3	176
10	Guidance for using pilot studies to inform the design of intervention trials with continuous outcomes. Clinical Epidemiology, 2018, Volume 10, 153-157.	3.0	137
11	Confounding and Simpson's paradox. BMJ: British Medical Journal, 1994, 309, 1480-1481.	2.3	132
12	Computer Therapy Compared With Usual Care for People With Long-Standing Aphasia Poststroke. Stroke, 2012, 43, 1904-1911.	2.0	119
13	Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS): a multicentre, single-blinded, randomised controlled trial. Lancet Neurology, The, 2019, 18, 821-833.	10.2	116
14	Measurement in clinical trials: A neglected issue for statisticians?. Statistics in Medicine, 2009, 28, 3189-3209.	1.6	115
15	Sample Sizes for Clinical Trials. , 0, , .		98
16	WHY ARE PHARMACOKINETIC DATA SUMMARIZED BY ARITHMETIC MEANS?. Journal of Biopharmaceutical Statistics, 2000, 10, 55-71.	0.8	90
17	DELTA <sup>2</sup> guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. BMJ: British Medical Journal, 2018, 363, k3750.	2.3	90
18	At-risk children with asthma (ARC): a systematic review. Thorax, 2018, 73, 813-824.	5.6	87

#	Article	IF	CITATIONS
19	Automated telephone communication systems for preventive healthcare and management of long-term conditions. The Cochrane Library, 2016, 2016, CD009921.	2.8	83
20	Practical guide to sample size calculations: nonâ€inferiority and equivalence trials. Pharmaceutical Statistics, 2016, 15, 80-89.	1.3	74
21	Two-sided confidence intervals for the single proportion: comparison of seven methods by Robert G. Newcombe,Statistics in Medicine 1998;17:857–872. Statistics in Medicine, 2005, 24, 3383-3384.	1.6	71
22	A theory-based online health behaviour intervention for new university students (U@Uni): results from a randomised controlled trial. BMC Public Health, 2014, 14, 563.	2.9	71
23	Adaptive designs undertaken in clinical research: a review of registered clinical trials. Trials, 2016, 17, 150.	1.6	66
24	Problems with the performance of the SF-36 among people with type 2 diabetes in general practice. Quality of Life Research, 2001, 10, 661-670.	3.1	63
25	Understanding Variation in Sets of N-of-1 Trials. PLoS ONE, 2016, 11, e0167167.	2.5	59
26	The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ, The, 2020, 369, m115.	6.0	57
27	Sample size calculations for clinical studies allowing for uncertainty about the variance. Pharmaceutical Statistics, 2006, 5, 29-37.	1.3	52
28	A theory-based online health behaviour intervention for new university students (U@Uni:LifeGuide): results from a repeat randomized controlled trial. Trials, 2015, 16, 555.	1.6	51
29	DELTA2 guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. Trials, 2018, 19, 606.	1.6	50
30	The disagreeable behaviour of the kappa statistic. Pharmaceutical Statistics, 2015, 14, 74-78.	1.3	47
31	Investigating variability in patient response to treatment – a case study from a replicate cross-over study. Statistical Methods in Medical Research, 2011, 20, 657-666.	1.5	46
32	Tutorial in biostatistics: sample sizes for parallel group clinical trials with binary data. Statistics in Medicine, 2012, 31, 2904-2936.	1.6	40
33	Moving statistics beyond the individual clinical trial: applying decision science to optimize a clinical development plan. Pharmaceutical Statistics, 2005, 4, 37-46.	1.3	38
34	Clinical and cost effectiveness of computer treatment for aphasia post stroke (Big CACTUS): study protocol for a randomised controlled trial. Trials, 2015, 16, 18.	1.6	37
35	Practical guide to sample size calculations: an introduction. Pharmaceutical Statistics, 2016, 15, 68-74.	1.3	34
36	Are pilot trials useful for predicting randomisation and attrition rates in definitive studies: A review of publicly funded trials. Clinical Trials, 2018, 15, 189-196.	1.6	34

#	Article	lF	CITATIONS
37	Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care Patient Population Including Both Tested and Untested Patients. Journal of Pragmatic and Observational Research, 2021, Volume 12, 93-104.	1.5	32
38	Missing steps in a staircase: a qualitative study of the perspectives of key stakeholders on the use of adaptive designs in confirmatory trials. Trials, 2015, 16, 430.	1.6	31
39	An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review. PLoS ONE, 2015, 10, e0141104.	2.5	31
40	How Biased Are Indirect Comparisons, Particularly When Comparisons Are Made Over Time in Controlled Trials?. Drug Information Journal, 2008, 42, 625-633.	0.5	28
41	Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. BMC Medicine, 2018, 16, 210.	5.5	28
42	Progression criteria in trials with an internal pilot: an audit of publicly funded randomised controlled trials. Trials, 2019, 20, 493.	1.6	28
43	Sample sizes for estimation in clinical research. Pharmaceutical Statistics, 2004, 3, 213-215.	1.3	27
44	Increases in asthma hospital admissions associated with the end of the summer vacation for school-age children with asthma in two cities from England and Scotland. Public Health, 2007, 121, 482-484.	2.9	27
45	Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT. Health Technology Assessment, 2020, 24, 1-176.	2.8	24
46	Seasonality of medical contacts in school-aged children with asthma: Association with school holidays. Public Health, 2011, 125, 769-776.	2.9	23
47	A theory-based online health behavior intervention for new university students: study protocol. BMC Public Health, 2013, 13, 107.	2.9	23
48	A comparison of methods for sample size estimation for non-inferiority studies with binary outcomes. Statistical Methods in Medical Research, 2011, 20, 595-612.	1.5	22
49	Sample sizes for trials involving multiple correlated mustâ€win comparisons. Pharmaceutical Statistics, 2012, 11, 177-185.	1.3	21
50	Designing clinical trials with uncertain estimates of variability. Pharmaceutical Statistics, 2004, 3, 261-268.	1.3	18
51	Issues with number needed to treat. Statistics in Medicine, 2005, 24, 3233-3235.	1.6	18
52	Efficacy and suicidal risk for antidepressants in paediatric and adolescent patients. Statistical Methods in Medical Research, 2013, 22, 190-218.	1.5	18
53	A Review of Clinical Trials With an Adaptive Design and Health Economic Analysis. Value in Health, 2019, 22, 391-398.	0.3	18
54	Preventing and lessening exacerbations of asthma in school-age children associated with a new term (PLEASANT): study protocol for a cluster randomised control trial. Trials, 2013, 14, 297.	1.6	17

#	Article	IF	CITATIONS
55	Rehabilitation of older patients: day hospital compared with rehabilitation at home. Clinical outcomes. Age and Ageing, 2011, 40, 557-562.	1.6	16
56	Proposed best practice for statisticians in the reporting and publication of pharmaceutical industryâ€sponsored clinical trials. Pharmaceutical Statistics, 2011, 10, 70-73.	1.3	16
57	The potential for bias in reporting of industryâ€sponsored clinical trials. Pharmaceutical Statistics, 2011, 10, 74-79.	1.3	16
58	An investigation of the impact of futility analysis in publicly funded trials. Trials, 2014, 15, 61.	1.6	16
59	Why do we use pooled variance analysis of variance?. Pharmaceutical Statistics, 2005, 4, 3-5.	1.3	15
60	The ABC of nonâ€inferiority margin setting from indirect comparisons. Pharmaceutical Statistics, 2011, 10, 448-453.	1.3	15
61	Practical help for specifying the target difference in sample size calculations for RCTs: the DELTA2 five-stage study, including a workshop. Health Technology Assessment, 2019, 23, 1-88.	2.8	15
62	Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trials. Trials, 2015, 16, 585.	1.6	14
63	Practical guide to sample size calculations: superiority trials. Pharmaceutical Statistics, 2016, 15, 75-79.	1.3	14
64	Pilot Studies in clinical research. Statistical Methods in Medical Research, 2016, 25, 995-996.	1.5	14
65	Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study. Pharmacoeconomics, 2017, 35, 561-573.	3.3	13
66	Predicting where future means will lie based on the results of the current trial. Contemporary Clinical Trials, 2007, 28, 352-357.	1.8	12
67	PPI in the PLEASANT trial: involving children with asthma and their parents in designing an intervention for a randomised controlled trial based within primary care. Primary Health Care Research and Development, 2016, 17, 536-548.	1.2	12
68	Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM): study protocol for a randomised controlled trial. Trials, 2018, 19, 578.	1.6	12
69	Are hospital league tables calculated correctly?. Public Health, 2007, 121, 902-904.	2.9	11
70	Issues with using baseline in last observation carried forward analysis. Pharmaceutical Statistics, 2008, 7, 142-146.	1.3	11
71	Atmospheric pressure and sudden infant death syndrome in Cook County, Chicago. Paediatric and Perinatal Epidemiology, 2001, 15, 287-289.	1.7	10
72	A personal perspective on the Royal Statistical Society report of the working party on statistical issues in first-in-man studies. Pharmaceutical Statistics, 2007, 6, 75-78.	1.3	10

#	Article	IF	CITATIONS
73	Choosing the target difference (â€~effect size') for a randomised controlled trial - DELTA2 guidance protocol. Trials, 2017, 18, 271.	1.6	10
74	The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials, 2020, 21, 528.	1.6	10
75	Estimating effect sizes for health-related quality of life outcomes. Statistical Methods in Medical Research, 2014, 23, 430-439.	1.5	9
76	Self-managed, computerised word finding therapy as an add-on to usual care for chronic aphasia post-stroke: An economic evaluation. Clinical Rehabilitation, 2021, 35, 703-717.	2.2	9
77	A postal survey of the quality of long-term institutional care. International Journal of Geriatric Psychiatry, 1994, 9, 619-625.	2.7	8
78	LETTER TO THE EDITOR: SAMPLE SIZES CALCULATIONS FOR ORDERED CATEGORICAL DATA by J. Whitehead,Statistics in Medicine, 12, 2257-2272 (1993) , 1996, 15, 1065-1066.		8
79	The ABC of pharmaceutical trial design: some basic principles. Pharmaceutical Statistics, 2002, 1, 45-53.	1.3	7
80	Making available information from studies sponsored by the pharmaceutical industry: some current practices. Pharmaceutical Statistics, 2011, 10, 60-69.	1.3	7
81	Investigating the assumption of homogeneity of treatment effects in clinical studies with application to metaâ€analysis. Pharmaceutical Statistics, 2012, 11, 49-56.	1.3	7
82	NOURISH, Nutritional OUtcomes from a Randomised Investigation of Intradialytic oral nutritional Supplements in patients receiving Haemodialysis: a pilot randomised controlled trial. Pilot and Feasibility Studies, 2015, 1, 11.	1.2	7
83	Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial $\hat{a} \in $ the development of the DELTA2 guidance. Trials, 2018, 19, 542.	1.6	7
84	Letter to the Editors. Biometrics, 2004, 60, 284-284.	1.4	6
85	Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity. BMC Medical Research Methodology, 2017, 17, 149.	3.1	6
86	Sample sizes for cluster-randomised trials with continuous outcomes: Accounting for uncertainty in a single intra-cluster correlation estimate. Statistical Methods in Medical Research, 2021, 30, 2459-2470.	1.5	6
87	Influence of Adaptive Analysis on Unnecessary Patient Recruitment: Reanalysis of the RATPAC Trial. Annals of Emergency Medicine, 2012, 60, 442-448.e1.	0.6	5
88	Seven useful designs. Pharmaceutical Statistics, 2012, 11, 24-31.	1.3	4
89	Can emergency medicine research benefit from adaptive design clinical trials?. Emergency Medicine Journal, 2017, 34, 243-248.	1.0	4
90	Calculation of confidence intervals for a finite population size. Pharmaceutical Statistics, 2019, 18, 115-122.	1.3	4

#	Article	IF	CITATIONS
91	How can health economics be used in the design and analysis of adaptive clinical trials? A qualitative analysis. Trials, 2020, 21, 252.	1.6	4
92	Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials. Medical Decision Making, 2022, 42, 461-473.	2.4	4
93	Adjusting for bias in the mean for primary and secondary outcomes when trials are in sequence. Pharmaceutical Statistics, 2022, 21, 460-475.	1.3	4
94	Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design by L. Frison and S.J. Pocock,Statistics in Medicine 1992; 12: 1685-1704. Statistics in Medicine, 2000, 19, 3133-3135.	1.6	3
95	Nutritional outcomes from a randomised investigation of intradialytic oral nutritional supplements in patients receiving haemodialysis, (NOURISH): a protocol for a pilot randomised controlled trial. SpringerPlus, 2013, 2, 515.	1.2	3
96	Characteristics of patients in platform C19, a COVID-19 research database combining primary care electronic health record and patient reported information. PLoS ONE, 2021, 16, e0258689.	2.5	2
97	Open-label, cluster randomised controlled trial and economic evaluation of a brief letter from a GP on unscheduled medical contacts associated with the start of the school year: the PLEASANT trial. BMJ Open, 2018, 8, e017367.	1.9	2
98	Are we getting what we pay for?. Public Health, 2006, 120, 1013-1019.	2.9	1
99	Time to end the nonâ€inferiority complex?. Pharmaceutical Statistics, 2011, 10, 393-394.	1.3	1
100	Statistical issues in drug development. Statistical Methods in Medical Research, 2011, 20, 577-578.	1.5	1
101	Environmental triggers of hospital admissions for school-age children with asthma in two British cities: Figure 1. Emergency Medicine Journal, 2012, 29, 844-845.	1.0	1
102	A survey of birth order status of students studying for medical degree at the University of Sheffield. JRSM Open, 2014, 5, 205427041453332.	0.5	1
103	Protocol for a systematic review to identify and weight the indicators of risk of asthma exacerbations in children aged 5–12 years. Npj Primary Care Respiratory Medicine, 2017, 27, 16088.	2.6	1
104	LETTER TO THE EDITOR: SAMPLE SIZES CALCULATIONS FOR ORDERED CATEGORICAL DATA by J. Whitehead, Statistics in Medicine, 12, 2257–2272 (1993) Statistics in Medicine, 1996, 15, 1065-1066.	1.6	1
105	Literature review October–December 2006. Pharmaceutical Statistics, 2007, 6, 67-68.	1.3	Ο
106	Authors' Rejoinder to Commentaries on â€ <sup>~</sup> Measurement in clinical trials: A neglected issue for statisticians?'. Statistics in Medicine, 2009, 28, 3223-3225.	1.6	0
107	Meta-analysis in clinical research. Statistical Methods in Medical Research, 2013, 22, 115-116.	1.5	0
108	The analysis of the use of â€~unascertained' for sudden unexpected deaths in infancy from 1988 to 2010. Archives of Disease in Childhood, 2014, 99, 300-301.	1.9	0

#	Article	IF	CITATIONS
109	Corrections: The disagreeable behaviour of the kappa statistic. Pharmaceutical Statistics, 2017, 16, 95-95.	1.3	Ο
110	Practical guide to sample size calculations: Installation of the app <scp>SampSize</scp> . Pharmaceutical Statistics, 2022, , .	1.3	0